When a Concussion Unleashes Something Deeper

The Clinical Paradox

A 34-year-old patient presents six months post-mild TBI with persistent cognitive dysfunction, migrating pain, headaches, sensory intolerance, memory issuses, dysautonomia, and treatment-resistant fatigue. Neuroimaging: unremarkable. Standard labs: within normal limits. The diagnosis defaults to post-concussion syndrome—until someone looks into tick-borne disease.

This scenario repeats across practices with troubling frequency. What we're witnessing isn't diagnostic failure—it's a collision between two poorly understood conditions that share overlapping pathophysiology: traumatic brain injury and chronic tick-borne illness

In a retrospective review published by our esteemed faculty members, Dr. Sergio Azzolino, Dr. Ahmed Hankir, and Dr. Ted Carrick in Psychiatria Danubina, they found that more than one‑third (37.7%) of patients with chronic post‑concussive symptoms had serologic evidence of Lyme disease on Western blot testing, highlighting a statistically significant association between persistent PCS and undiagnosed infection.

Their findings complement more recent mechanistic models from Johns Hopkins and other institutions showing persistent neuroinflammation and cytokine dysregulation in both Lyme disease and post‑TBI. Taken together, this dual pathology — observed clinically by Azzolino and colleagues and explained mechanistically by modern imaging research — suggests a unified neuroimmune continuum rather than two separate disorders.

Thea Neuroinflammatory Convergence

Traumatic brain injury initiates a cascade of immune activation that extends far beyond the acute injury phase. 2024 research demonstrates that even mild TBI triggers:

• Sustained microglial activation and astrogliosis
• Elevated pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) persisting months post-injury
• Blood-brain barrier disruption allowing peripheral immune cell infiltration
• Systemic immune dysregulation with both hyperactivation and subsequent immunosuppression

This biphasic immune response creates a vulnerability window. The initial inflammatory surge damages neural tissue, while the subsequent immunosuppressive phase may unmask latent infections or allow subclinical infections to flourish.

Borrelia's Neurotropism

Borrelia burgdorferi and related spirochetes demonstrate remarkable neuroinvasive capacity. They cross the blood-brain barrier within days of infection, establishing persistent presence in the CNS even after standard antibiotic treatment. The organism's ability to form biofilms, persist in protected niches, and evade immune surveillance means that many patients harbor chronic, low-grade CNS infection.

Johns Hopkins neuroimaging studies (2024-2025) reveal measurable white matter abnormalities and persistent neuroinflammation in post-treatment Lyme disease patients—findings that mirror those seen in persistent post-concussion syndrome. The overlap isn't coincidental.

The Synergistic Effect

When TBI occurs in a patient with undiagnosed or inadequately treated Lyme disease, the results are multiplicative rather than additive. A 2024 study from the University of Denver demonstrated that individuals with combined infection and brain injury history show significantly worse neurological and psychological outcomes than those with either condition alone.

The mechanism appears to involve:

• TBI-induced BBB disruption facilitating spirochete CNS access
• Shared inflammatory pathways amplifying neuroinflammation
• Mitochondrial dysfunction from both conditions creating severe energy deficit
• Overlapping autonomic dysregulation

Beyond Lyme: The Coinfection Complexity

The Polymicrobial Reality

Ticks are vectors for multiple pathogens simultaneously. A single Ixodes tick may transmit:

• Borrelia burgdorferi (Lyme disease)
• Babesia species (causing malaria-like illness)
• Bartonella species (neuropsychiatric and vascular effects)
• Anaplasma phagocytophilum (immune suppression)
• Relapsing fever Borrelia (distinct from Lyme)
• Ehrlichia species
• Powassan virus (direct neuroinvasion)

Each pathogen contributes distinct symptomatology. Babesia causes air hunger, night sweats, and temperature dysregulation. Bartonella produces neuropsychiatric symptoms, including anxiety, rage episodes, and neuropathic pain—often misattributed to post-concussion mood changes. Relapsing fever Borrelia creates cyclical symptom patterns that confound diagnosis.

The Diagnostic Blind Spot

Standard two-tier Lyme testing (ELISA followed by Western blot) misses 50-60% of cases, particularly in:

• Early infection (before antibody development)
• Chronic infection (immune exhaustion/tolerance)
• Immunosuppressed patients (including post-TBI)
• Infections with non-burgdorferi species

Coinfection testing is even more problematic. Many labs lack validated assays for Bartonella species or relapsing fever Borrelia. Babesia requires specific PCR or fluorescent microscopy that isn't routinely ordered.

The Horowitz MSIDS Questionnaire: Clinical Utility

Evidence Base

The Horowitz Multiple Systemic Infectious Disease Syndrome (MSIDS) questionnaire underwent empirical validation in 2017, demonstrating:

• High sensitivity for identifying patients with tick-borne disease
• Ability to differentiate Lyme/coinfection patients from controls
• Correlation with disease severity and treatment response
• Cost-effectiveness as a screening tool

The 38-point questionnaire systematically assesses symptom domains commonly affected by tick-borne illness: neurological, musculoskeletal, cardiac, psychiatric, and systemic. Scores >46 indicate high probability of tick-borne disease; scores 21-45 suggest possible involvement.

Clinical Application

For the holistic physician, the MSIDS questionnaire serves multiple functions:

1. Pattern Recognition: It forces systematic review of symptom domains that might otherwise be dismissed as "functional" or "psychosomatic"
2. Documentation: It provides quantifiable baseline for tracking treatment response
3. Patient Validation: It signals to patients that their complex symptom picture is recognized and taken seriously
4. Testing Justification: It provides clinical rationale for pursuing specialized testing that insurance may initially deny

Critical Caveat

The questionnaire is a screening tool, not a diagnostic instrument. High scores warrant further investigation—they don't confirm diagnosis. Conversely, lower scores don't exclude tick-borne disease in patients with strong clinical suspicion.

Diagnostic Strategy for the Post-TBI Patient

When to Suspect Tick-Borne Disease

Consider tick-borne illness in post-TBI patients with:

• Symptoms persisting >3 months despite appropriate concussion management
• Migratory or cyclical symptom patterns
• Disproportionate fatigue relative to injury severity
• Dysautonomia (POTS-like symptoms)
• New-onset anxiety/depression with atypical features
• Neuropathic pain or paresthesias
• Cognitive dysfunction exceeding expected TBI sequelae

Testing Approach

Standard testing often fails. Consider:

1. Specialized Lyme Testing (Panels that include):
   • IgM and IgG Western blots with expanded band reporting
   • Borrelia species beyond burgdorferi
   • CD57 natural killer cell count (immune marker)
2. Coinfection Panels:
   • Babesia PCR and fluorescent microscopy
   • Bartonella serology and PCR (Galaxy Diagnostics ePCR)
   • Anaplasma/Ehrlichia PCR
   • Relapsing fever Borrelia testing
3. Functional Markers:
   • Inflammatory cytokines (IL-6, TNF-α, TGF-β1)
   • CD57 count
   • C4a complement (mold/biotoxin marker often elevated in Lyme)
   • Organic acids (mitochondrial function)
4. Advanced Imaging: Consider functional MRI or PET scanning if available—may reveal hypometabolism or inflammation missed on standard MRI

Treatment Considerations

The Integrative Approach

Treatment must address both the infection and the neuroinflammatory cascade:

Antimicrobial Strategy:

• Extended antibiotic protocols (often months, not weeks)
• Combination therapy for coinfections
• Biofilm disruptors (NAC, lumbrokinase)
• Pulsed dosing to address persister cells

Neuroinflammation Management:

• Low-dose naltrexone (microglial modulation)
• Omega-3 fatty acids (EPA/DHA at therapeutic doses)
• Curcumin and resveratrol (NF-κB pathway inhibition)
• Specialized pro-resolving mediators (SPMs)

Mitochondrial Support:

• CoQ10, PQQ, alpha-lipoic acid
• B-vitamin complex (methylated forms)
• Magnesium threonate (CNS penetration)
• D-ribose for cellular energy

Detoxification Support:

• Binders (cholestyramine, activated charcoal) for neurotoxin clearance
• Glutathione support (NAC, liposomal glutathione)
• Liver support (milk thistle, phosphatidylcholine)

Autonomic Rehabilitation:

• Graded exercise therapy (carefully titrated)
• Heart rate variability training
• Vagal nerve stimulation techniques

The Broader Implications

Shifting the Paradigm

The TBI-Lyme interface challenges several assumptions:

1. Post-concussion syndrome may be a diagnosis of exclusion—but we're not excluding enough. Routine workup rarely includes tick-borne disease screening.
2. "Normal" labs don't mean normal physiology. Neuroinflammation, immune dysfunction, and chronic infection can exist without abnormal CBC, CMP, or standard MRI.
3. Symptom persistence isn't psychological failure. When patients don't recover as expected, the default shouldn't be "anxiety" or "somatization"—it should be "what are we missing?"

Policy and Research Directions

The federal landscape is shifting. HHS initiatives, including the LymeX Innovation Accelerator, are pushing for:

• Better diagnostic tools (direct detection methods, not just serology)
• Recognition of persistent Lyme-associated illness
• Research into the Lyme-long COVID-post-viral syndrome overlap
• Improved treatment protocols for chronic presentations

For clinicians, this means staying current with evolving diagnostic criteria and treatment approaches that extend beyond IDSA guidelines.

Clinical Takeaways

1. Screen systematically: Use the MSIDS questionnaire for any post-TBI patient with persistent, unexplained symptoms
2. Test appropriately: Standard Lyme testing misses most cases—use specialized labs and comprehensive coinfection panels
3. Think polymicrobial: Assume coinfections until proven otherwise
4. Treat the inflammation: Antimicrobials alone often fail—address neuroinflammation, mitochondrial dysfunction, and immune dysregulation
5. Validate the patient: These patients have often been dismissed repeatedly—clinical validation is therapeutic

The intersection of TBI and tick-borne disease represents a diagnostic blind spot with profound implications for patient outcomes. As holistic physicians, we're uniquely positioned to see the whole picture—to recognize that "post-concussion syndrome" may be the presenting symptom of something far more complex, and far more treatable, than conventional medicine acknowledges.

The Azzolino et al. (2019) study provides early empirical support for what many clinicians now suspect: that a subset of long‑term post‑concussion symptoms may reflect unresolved infectious neuroinflammation rather than purely mechanical brain injury. The question isn't whether we can afford to screen for tick-borne disease in persistent post-TBI patients. It's whether we can afford not to.

REFERENCES

Neuroimaging and Post-Treatment Lyme Disease

1. Azzolino S, Zaman R, Hankir A, Carrick FR. The prevalence of Lyme disease and associated co‑infections in people with a chronic post‑concussive syndrome. Psychiatr Danub. 2019; 31(Suppl 3): 219‑221.
   
   • https://pubmed.ncbi.nlm.nih.gov/31488744/
2. Aucott JN, Rebman AW, Crowder LA, et al. Early brain changes in Lyme disease are associated with clinical outcomes. medRxiv. 2024. doi:10.1101/2024.12.16.24319088
   • Available at: https://www.medrxiv.org/content/10.1101/2024.12.16.24319088v3
3. Aucott JN, Rebman AW, Crowder LA, et al. Johns Hopkins Neuroimaging Study Reveals Functional and Structural Brain Abnormalities in People with Post-Treatment Lyme Disease. Johns Hopkins Medicine News. October 26, 2022.
   • Available at: https://www.hopkinsmedicine.org/news/newsroom/news-releases/2022/10/johns-hopkins-neuroimaging-study-reveals-functional-and-structural-brain-abnormalities-in-people-with-post-treatment-lyme-disease
4. Johns Hopkins Lyme Disease Research Center. Early Brain Response Linked to Recovery from Lyme Disease. 2024.
   • Available at: https://www.hopkinslyme.org/research/early-brain-response-linked-to-recovery-from-lyme-disease/

Horowitz MSIDS Questionnaire Validation

1. Citera M, Freeman PR, Horowitz RI. Empirical validation of the Horowitz Multiple Systemic Infectious Disease Syndrome Questionnaire for suspected Lyme disease. Int J Gen Med. 2017;10:249-273. doi:10.2147/IJGM.S140224
   • Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC5590688/
2. Citera M, Freeman PR, Horowitz RI. Empirical validation of the Horowitz Multiple Systemic Infectious Disease Syndrome Questionnaire for suspected Lyme disease. PubMed. 2017 Sep 13;10:249-273. PMID: 28919803
   • Available at: https://pubmed.ncbi.nlm.nih.gov/28919803/

Traumatic Brain Injury and Neuroinflammation

1. Sulhan S, Lyon KA, Shapiro LA, Huang JH. Neuroinflammation and blood-brain barrier disruption following traumatic brain injury: Pathophysiology and potential therapeutic targets. J Neurosci Res. 2020;98(1):19-28.
   • Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12378500/
2. Karve IP, Taylor JM, Crack PJ. The contribution of astrocytes and microglia to traumatic brain injury. Br J Pharmacol. 2016;173(4):692-702.
   • Available at: https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1334847/full
3. Simon DW, McGeachy MJ, Bayır H, et al. Targeting neuroinflammation to enhance recovery after brain injury. Ann Med Surg (Lond). 2024.
   • Available at: https://journals.lww.com/annals-of-medicine-and-surgery/fulltext/9900/targeting_neuroinflammation_to_enhance_recovery.4162.aspx
4. Corps KN, Roth TL, McGavern DB. Inflammation and neuroprotection in traumatic brain injury. JAMA Neurol. 2015;72(3):355-362.
   • Available at: https://onlinelibrary.wiley.com/doi/10.1111/imr.13419

Combined Infection and Brain Injury

1. Krukowski K. Investigating Chronic Post-Infection and Post-Injury Symptom Overlap. University of Denver Electronic Theses and Dissertations. 2024.
   • Available at: https://digitalcommons.du.edu/etd/2496/

Borrelia Neuroinvasion and Persistence

1. Ramesh G, Borda JT, Dufour J, et al. Interaction of the Lyme disease spirochete Borrelia burgdorferi with brain parenchyma elicits inflammatory mediators from glial cells as well as glial and neuronal apoptosis. Am J Pathol. 2008;173(5):1415-1427.
   • Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8232152/
2. Parthasarathy G, Fevrier HB, Philipp MT. Lyme Neuroborreliosis: Mechanisms of B. burgdorferi Infection of the Nervous System. Pathogens. 2021;10(6):730. doi:10.3390/pathogens10060730
   • Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8232152/
3. Sapi E, Kaur N, Anyanwu S, et al. Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi. Infect Drug Resist. 2011;4:97-113.
   • Available at: https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2017.00276/full

Tick-Borne Coinfections

1. Maggi RG, Mozayeni BR, Pultorak EL, et al. Bartonella and Babesia Co-Infection Detected in Patients with Chronic Illness. North Carolina State University News. July 2024.
   • Available at: https://news.ncsu.edu/2024/07/bartonella-and-babesia-co-infection-detected-in-patients-with-chronic-illness/
2. Moutailler S, Valiente Moro C, Vaumourin E, et al. Meta-analysis of tick-borne and other pathogens: Co-infection dynamics in natural populations. PLoS Negl Trop Dis. 2024.
   • Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11525461/
3. Lantos PM, Wormser GP. Chronic coinfections in patients diagnosed with chronic Lyme disease: a systematic review. Am J Med. 2014;127(11):1105-1110.
   • Available at: https://www.lymedisease.org/tick-borne-coinfections/
4. Diuk-Wasser MA, Vannier E, Krause PJ. Global prevalence of Borrelia burgdorferi, Anaplasma phagocytophilum, and Babesia microti coinfection in Ixodes scapularis ticks. Ticks Tick Borne Dis. 2025.
   • Available at: https://www.sciencedirect.com/science/article/pii/S2052297525000605

Diagnostic Limitations

1. Cook MJ, Puri BK. Commercial test kits for detection of Lyme borreliosis: a meta-analysis of test accuracy. Int J Gen Med. 2016;9:427-440.
   • Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC4918152/
2. Waddell LA, Greig J, Mascarenhas M, et al. The accuracy of diagnostic tests for Lyme disease in humans, a systematic review and meta-analysis of North American research. PLoS One. 2016;11(12):e0168613.
   • Available at: https://news.mayocliniclabs.com/2021/10/06/modified-two-tiered-testing-for-lyme-disease/
3. Branda JA, Strle K, Nigrovic LE, et al. Evaluation of modified 2-tiered serodiagnostic testing algorithms for early Lyme disease. Clin Infect Dis. 2017;64(8):1074-1080.
   • Available at: https://www.columbia-lyme.org/diagnosis

Federal Policy and Research Initiatives

1. U.S. Department of Health and Human Services. Tick-Borne Diseases and Associated Illnesses: Updated Scoping Review. 2024.
   • Available at: https://www.hhs.gov/sites/default/files/2024-tbd-scoping-review.pdf
2. HHS Office of the Assistant Secretary for Health. LymeX Innovation Accelerator. 2024.
   • Available at: https://www.hhs.gov/ash/osm/innovationx/lymex/index.html

‍